Clinical Trial Update: A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching to the fixed-dose combination Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) in people with HIV-1 who exp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: HIV-1 | Phase 4 | Status: COMPLETED | Results posted: 2024-08-27